The unique potency of Cowpea mosaic virus (CPMV)
Journal
Biomaterials science
ISSN: 2047-4849
Titre abrégé: Biomater Sci
Pays: England
ID NLM: 101593571
Informations de publication
Date de publication:
30 Sep 2020
30 Sep 2020
Historique:
pubmed:
12
9
2020
medline:
15
5
2021
entrez:
11
9
2020
Statut:
ppublish
Résumé
The immunosuppressive tumor microenvironment enables cancer to resist immunotherapies. We have established that intratumoral administration of plant-derived Cowpea mosaic virus (CPMV) nanoparticles as an in situ vaccine overcomes the local immunosuppression and stimulates a potent anti-tumor response in several mouse cancer models and canine patients. CPMV does not infect mammalian cells but acts as a danger signal that leads to the recruitment and activation of innate and subsequently, adaptive immune cells. In the present study we addressed whether other icosahedral viruses or virus-like particles (VLPs) of plant, bacteriophage and mammalian origin can be similarly employed as intratumoral immunotherapy. Our results indicate that CPMV in situ vaccine outperforms Cowpea chlorotic mottle virus (CCMV), Physalis mosaic virus (PhMV), Sesbania mosaic virus (SeMV), bacteriophage Qβ VLPs, or Hepatitis B virus capsids (HBVc). Furthermore, ex vivo and in vitro assays reveal unique features of CPMV that makes it an inherently stronger immune stimulant.
Identifiants
pubmed: 32914796
doi: 10.1039/d0bm01219j
pmc: PMC8086234
mid: NIHMS1693247
doi:
Substances chimiques
Cancer Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5489-5503Subventions
Organisme : NCI NIH HHS
ID : P30 CA023108
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA224605
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA218292
Pays : United States
Références
Virology. 1999 Dec 5;265(1):20-34
pubmed: 10603314
J Virol Methods. 2007 Apr;141(1):84-6
pubmed: 17188758
Biomacromolecules. 2017 Dec 11;18(12):4141-4153
pubmed: 29144726
Cancer Manag Res. 2018 Dec 05;10:6685-6693
pubmed: 30584363
J Virol. 2007 Feb;81(4):1632-40
pubmed: 17121801
ACS Omega. 2018 Apr 30;3(4):3702-3707
pubmed: 29732445
Adv Ther (Weinh). 2019 May;2(5):
pubmed: 33969181
ACS Appl Mater Interfaces. 2019 May 22;11(20):18213-18223
pubmed: 31074602
Curr Opin Oncol. 2013 Nov;25(6):637-45
pubmed: 24076584
Biomacromolecules. 2016 Feb 8;17(2):641-8
pubmed: 26765848
J Virol. 2019 Oct 15;93(21):
pubmed: 31375592
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
mBio. 2017 Nov 14;8(6):
pubmed: 29138299
Immunology. 2020 Feb;159(2):183-192
pubmed: 31630392
Nano Lett. 2019 Mar 13;19(3):2099-2105
pubmed: 30801195
Protein Sci. 2017 Nov;26(11):2170-2180
pubmed: 28795465
PLoS One. 2015 Sep 09;10(9):e0136180
pubmed: 26352137
Proc Natl Acad Sci U S A. 2015 Mar 31;112(13):3892-7
pubmed: 25775582
Nat Med. 2004 Sep;10(9):950-8
pubmed: 15334073
J Clin Invest. 2018 Apr 2;128(4):1258-1260
pubmed: 29504947
Antimicrob Agents Chemother. 2014;58(3):1738-43
pubmed: 24395226
Cancers (Basel). 2019 Apr 10;11(4):
pubmed: 30974896
J Exp Med. 2011 Sep 26;208(10):2005-16
pubmed: 21930765
J Virol. 2017 Jul 27;91(16):
pubmed: 28566373
Nat Biotechnol. 2006 Mar;24(3):358-62
pubmed: 16474383
J Mol Biol. 1997 Oct 3;272(4):541-52
pubmed: 9325111
Nat Nanotechnol. 2016 Mar;11(3):295-303
pubmed: 26689376
Nat Immunol. 2010 May;11(5):373-84
pubmed: 20404851
Chembiochem. 2011 Nov 4;12(16):2435-40
pubmed: 21953809
Mol Pharm. 2018 Sep 4;15(9):3717-3722
pubmed: 29613803
PLoS Pathog. 2009 May;5(5):e1000417
pubmed: 19412526
Chem Commun (Camb). 2002 Oct 21;(20):2390-1
pubmed: 12430455
J Virol Methods. 2002 Sep;105(2):343-8
pubmed: 12270666
Arch Virol. 2019 Feb;164(2):497-507
pubmed: 30430265
Arch Virol. 2001;146(2):209-23
pubmed: 11315633
ACS Nano. 2019 Jul 23;13(7):7442-7462
pubmed: 31180642
Chem Biol. 2004 Jun;11(6):855-63
pubmed: 15217618
Nucleic Acids Res. 2009 Jan;37(Database issue):D436-42
pubmed: 18981051
J Leukoc Biol. 2012 Jan;91(1):167-81
pubmed: 21954284
J Virol. 2014 May;88(10):5816-33
pubmed: 24623428
Virology. 2009 Oct 25;393(2):329-37
pubmed: 19733890
Cancer Cell. 2009 Sep 8;16(3):183-94
pubmed: 19732719
Int J Med Microbiol. 2008 Jan;298(1-2):135-42
pubmed: 17888729
PLoS One. 2009 Nov 23;4(11):e7981
pubmed: 19956734
Oncotarget. 2016 Jul 5;7(27):42195-42207
pubmed: 27259252
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Jan;12(1):e1579
pubmed: 31456339
Trends Immunol. 2015 Feb;36(2):92-101
pubmed: 25616716
Chembiochem. 2007 Jul 9;8(10):1131-6
pubmed: 17526061
Mol Pharm. 2018 Sep 4;15(9):3700-3716
pubmed: 29798673
Cell Microbiol. 2011 Sep;13(9):1358-70
pubmed: 21707907
Adv Drug Deliv Rev. 2017 May 15;114:206-221
pubmed: 28449873
Annu Rev Virol. 2016 Sep 29;3(1):429-451
pubmed: 27482896
Nat Rev Clin Oncol. 2014 Nov;11(11):630-2
pubmed: 25311350
J Mol Biol. 1999 Jun 18;289(4):905-18
pubmed: 10369771
Nano Lett. 2016 Mar 9;16(3):1826-32
pubmed: 26891174
J Immunol. 2009 Mar 1;182(5):3105-11
pubmed: 19234207
Eur J Immunol. 2014 Jun;44(6):1814-22
pubmed: 24510590